The company is reportedly seen as an attractive acquisition target due to its diversified operations across two segments.

(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") ...

Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical ...

The partnership will be a joint venture (JV) which the German pharma company will manage through its new Bayer LifeScience Centre (BLSC) unit, combining the 'molecular scissors' gene-editing ...

The company, which is headquartered in Bremen, Germany, was founded in 1985 and is a second-generation family business. The company specializes in grinding down particles used in pharmaceuticals ...

SpringWorks Therapeutics stock surged over Monday after a report from Reuters that German medical tech giant Merck KGaA could be close to acquiring the company.

An employee shows processed flowers of cannabis (marijuana) at the production site of German ... [+] pharmaceutical company Demecan for medical cannabis in Ebersbach near Dresden, eastern Germany ...

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with ...

X-Elio will supply 245GWh of clean energy annually to four pharmaceutical companies through its Lorca Solar project.